Risperidone extended release - Xbrane

Drug Profile

Risperidone extended release - Xbrane

Alternative Names: Risperisphere

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Primm srl
  • Developer Xbrane
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Aggression; Autistic disorder; Bipolar depression; Dementia; Schizophrenia

Most Recent Events

  • 05 Aug 2016 Chemical structure information added
  • 30 Oct 2015 Xbrane acquires Primm Pharma
  • 14 Oct 2015 Preclinical trials in Aggression in Sweden (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top